Medicus Pharma Ltd. Commo... (MDCX)
Medicus Pharma Common Stock Statistics
Share Statistics
Medicus Pharma Common Stock has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 277 |
| FTD / Avg. Volume | 0.51% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.2 and the forward PE ratio is null. Medicus Pharma Common Stock's PEG ratio is 0.08.
| PE Ratio | -2.2 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 7.46 |
| P/FCF Ratio | -2.28 |
| PEG Ratio | 0.08 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Medicus Pharma Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.1.
| Current Ratio | 2.33 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | -35.21 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 5.56, so Medicus Pharma Common Stock's price volatility has been higher than the market average.
| Beta | 5.56 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 3.47 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 58.05 |
| Average Volume (20 Days) | 54.8K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -11.18M |
| Net Income | -10.62M |
| EBITDA | -10.25M |
| EBIT | -10.25M |
| Earnings Per Share (EPS) | -1.1 |
Balance Sheet
The company has 4.16M in cash and 322.27K in debt, giving a net cash position of 3.84M.
| Cash & Cash Equivalents | 4.16M |
| Total Debt | 322.27K |
| Net Cash | 3.84M |
| Retained Earnings | -28.9M |
| Total Assets | 5.65M |
| Working Capital | 3.07M |
Cash Flow
In the last 12 months, operating cash flow was -10.25M and capital expenditures 0, giving a free cash flow of -10.25M.
| Operating Cash Flow | -10.25M |
| Capital Expenditures | 0 |
| Free Cash Flow | -10.25M |
| FCF Per Share | -1.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MDCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MDCX is $12, which is 200% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 200% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -2.32 |
| Piotroski F-Score | 1 |